Updates

Jagsonpal Pharmaceuticals Ltd ( ::.:&.mu • -~ Sakht Corporate Office: Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram -122015, Haryana (India) Ph.: +91124 4406710; E-mail: info@jagsonpal.com; Website: www.jagsonpal.com A CSR Initiative lJAGSONPAL! CIN. : L74899DL1978PLC009181 July 7, 2026 The Department of Corporate Services- Listing The Department of Corporate Services- Listing BSE Ltd, National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street Bandra Kurla Complex, Mumbai-400 001 Bandra (E) Mumbai – 400 051 Scrip Code: 507789 Symbol: JAGSNPHARM Subject: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir/ Madam, Please refer to the letter dated 29 June, 2026 wherein we had informed the Stock Exchanges regarding the proposed acquisition of equity stake in Aequitas Healthcare Private Limited ("Aequitas"). Out of the 85% stake proposed to be acquired in Aequitas, we have completed acquisition of 69.77% stake. Consequently, Aequitas has become a subsidiary of the Jagsonpal Pharmaceuticals Limited. We request you to take the above on record. Thanking you, For Jagsonpal Pharmaceuticals Limited Pratham Rawal Company Secretary & Compliance officer Regd. Office: Innov8, 3rd Floor, Plot No. 211, Okhla Phase-3, New Delhi-110020 (India) Mumbai Office: 13-14, Unit 3B, Phoenix Paragon Plaza, Kurla West, Mumbai, Maharashtra- 400070